All posts

Follow Us

LinkedInInstagramX
Quarterly ResultsArchiveLast updated 29 October 20263 min read

Colinz (COLINZ) Q2 FY27 Labs Profit Plunges 95% as One-Off Gain Fades

A one-time asset sale boosted profits last quarter, but Q2 reveals a core business with thin margins and negative cash flow.

By Anant Kacholia, HexaWealth Research · Created 29 October 2026

Colinz Laboratories reported a 12% yearly revenue rise in Q2 FY27, but profit collapsed 95% from the prior quarter. The plunge follows a one-off gain that flattered Q1 earnings, exposing ongoing margin pressure.

For a small pharmaceutical player like Colinz Labs, a quarter of explosive profit growth can be a mirage. The company’s September quarter shows why, as a 25% revenue jump was completely overshadowed by a 95% plunge in profit from the previous three months.

The headline numbers tell a story of divergence. Revenue grew 11.5% year-on-year to ₹1.55 crore. But profit fell 7.1% from a year ago to just ₹0.13 crore. The real shock is sequential: profit collapsed 94.6% from ₹2.4 crore in Q1.

Revenue & profit

Revenue (₹ Cr)

Profit (₹ Cr)

Revenue & profitQ2 FY26 1.39, Q3 FY26 1.43, Q4 FY26 1.75, Q1 FY27 1.24, Q2 FY27 1.55. Q2 FY26 0.14, Q3 FY26 0.08, Q4 FY26 0.17, Q1 FY27 2.40, Q2 FY27 0.1301234Q2 '26Q3 '26Q4 '26Q1 '27Q2 '27
  • Revenue (₹ Cr), Q2 FY26: 1.39
  • Revenue (₹ Cr), Q3 FY26: 1.43
  • Revenue (₹ Cr), Q4 FY26: 1.75
  • Revenue (₹ Cr), Q1 FY27: 1.24
  • Revenue (₹ Cr), Q2 FY27: 1.55
  • Profit (₹ Cr), Q2 FY26: 0.14
  • Profit (₹ Cr), Q3 FY26: 0.08
  • Profit (₹ Cr), Q4 FY26: 0.17
  • Profit (₹ Cr), Q1 FY27: 2.40
  • Profit (₹ Cr), Q2 FY27: 0.13

Revenue (₹ Cr)

Revenue (₹ Cr)Q2 FY26 1.39, Q3 FY26 1.43, Q4 FY26 1.75, Q1 FY27 1.24, Q2 FY27 1.5500.511.52Q2 '26Q3 '26Q4 '26Q1 '27Q2 '27
  • Revenue (₹ Cr), Q2 FY26: 1.39
  • Revenue (₹ Cr), Q3 FY26: 1.43
  • Revenue (₹ Cr), Q4 FY26: 1.75
  • Revenue (₹ Cr), Q1 FY27: 1.24
  • Revenue (₹ Cr), Q2 FY27: 1.55

Profit (₹ Cr)

Profit (₹ Cr)Q2 FY26 0.14, Q3 FY26 0.08, Q4 FY26 0.17, Q1 FY27 2.40, Q2 FY27 0.1301234Q2 '26Q3 '26Q4 '26Q1 '27Q2 '27
  • Profit (₹ Cr), Q2 FY26: 0.14
  • Profit (₹ Cr), Q3 FY26: 0.08
  • Profit (₹ Cr), Q4 FY26: 0.17
  • Profit (₹ Cr), Q1 FY27: 2.40
  • Profit (₹ Cr), Q2 FY27: 0.13

Net Profit Margin

Net Profit MarginQ2 FY26 10.2%, Q3 FY26 5.9%, Q4 FY26 9.8%, Q1 FY27 –, Q2 FY27 8.4%0%5%10%15%20%Q2 '26Q3 '26Q4 '26Q1 '27Q2 '27
  • Net Profit Margin, Q2 FY26: 10.2%
  • Net Profit Margin, Q3 FY26: 5.9%
  • Net Profit Margin, Q4 FY26: 9.8%
  • Net Profit Margin, Q1 FY27: –
  • Net Profit Margin, Q2 FY27: 8.4%
MetricCurrentQ2 FY27PreviousQ1 FY27Same quarter LYQ2 FY26
Revenue (₹ Cr)
1.55YoY +12%
1.24
1.39
Profit (₹ Cr)
0.13YoY -7.1%
2.40
0.14
Net Profit Margin
8.4%YoY -18%
–
10.2%

Why the profit vanished

This dramatic swing is not about operations. According to a report by scanx.trade, the previous quarter’s profit of ₹2.4 crore was inflated by a one-time gain of ₹2.76 crore from the sale of fixed assets. Strip that out, and the underlying profit trend is one of stagnation.

Even with that gain removed, profitability is under pressure. The net profit margin contracted by 180 basis points from a year ago to 8.4%. Scanx.trade notes that a higher tax provision and a 13% drop in other income squeezed the bottom line, even as pre-tax profit held flat.

A cash flow warning

Profit is one thing, but cash tells another story. For the first half of FY27, operating cash flow was negative, according to scanx.trade. This means the company’s modest profits are not yet translating into cash from its core business, a key sustainability risk for a small firm.

Live Chart

· COLINZ

(BSE)

ISIN: INE923C01011

The broader market context offers little shelter. While the Indian pharmaceutical market saw strong growth, with gynaecology therapies up 16.6% in September according to Equirus Securities, Colinz Labs has not disclosed any major new orders or product launches to capture this demand.

Key Points

  • Q2 profit of ₹0.13 crore plunged 95% from Q1, which was flattered by a one-time asset sale gain of ₹2.76 crore.
  • Core profitability weakened, with net margin down 180 bps year-on-year due to higher taxes and lower other income.
  • Operating cash flow was negative for H1 FY27, indicating profits are not backed by cash generation.
  • The company operates in a growing market but has shown no announced strategic initiatives to drive scale.

Hexa Perspective

The quarter reveals a company caught between two narratives. The one-off gain in Q1 created an illusion of breakout profitability that Q2 sharply corrects. The core business, while generating modest revenue growth, operates on thin margins with profitability highly dependent on non-operational income.

The negative operating cash flow is a red flag, suggesting working capital pressures even at this small scale. With no visible capex plans or new product launches, the path to sustainable growth remains unclear. Investors are left weighing a cheap valuation—a P/E of 6.2 against an industry average of 49.5—against the fundamental challenge of building a scalable, cash-generative operation.

Share or follow HexaWealth

Also read

Want this applied to your portfolio?

Talk to a HexaWealth advisor, or sync your mutual fund data for insights tailored to your holdings.

Frequently asked questions

What were Colinz Labs' Q2 FY27 results?
Colinz Laboratories reported revenue of ₹1.55 crore and a net profit of ₹0.13 crore for Q2 FY27, the quarter ended September 2026. Revenue grew 11.5% from a year ago, but profit declined 7.1% year-on-year and fell 94.6% from the previous quarter.
Did Colinz Labs' profit rise or fall in Q2 FY27?
Colinz Labs' profit fell in Q2 FY27. Net profit declined 7.1% compared to the same quarter last year and collapsed 94.6% from the immediately preceding quarter (Q1 FY27), dropping from ₹2.4 crore to ₹0.13 crore.
What is Colinz Labs' revenue for Q2 FY27?
Colinz Laboratories' revenue for Q2 FY27, the quarter ended September 2026, was ₹1.55 crore. This represents an 11.5% increase from the ₹1.39 crore reported in the same quarter of the previous fiscal year.
Why did Colinz Labs' profit drop 95% from last quarter?
The 95% quarterly profit drop is due to a one-time gain in Q1 FY27. According to scanx.trade, Q1 profit included a ₹2.76 crore gain from the sale of fixed assets. Q2 results reflect the company's underlying operational performance without that exceptional item.
What caused the margin contraction at Colinz Labs?
Colinz Labs' net profit margin contracted by 180 basis points year-on-year to 8.4%. Scanx.trade reports this was due to a higher effective tax burden and a 12.7% decline in other income, which pressured the bottom line despite stable pre-tax profit.
Is Colinz Labs' profit backed by cash?
No, Colinz Labs' profit is not currently backed by cash from operations. For the first half of FY27, the company's operating cash flow was negative, according to a scanx.trade report, indicating cash used in core business activities.
What is the outlook for Colinz Labs' core business?
The outlook is one of modest scale and thin margins. The company's core operational profit has been stagnant, and management has not announced new product launches or expansion plans. It operates in a growing pharmaceutical market but lacks a clear disclosed strategy for scaling up.
How does Colinz Labs' valuation compare to the industry?
Colinz Labs trades at a significant discount to the industry. Its price-to-earnings (P/E) ratio is 6.2, which is an 87.4% discount to the industry average P/E of 49.5, reflecting the market's assessment of its growth and profitability challenges.
Did institutional investors change their stake in Colinz Labs?
No, foreign and domestic institutional investors (FII/DII) held a 0% stake in Colinz Labs as of the latest data. According to stockfin.ai, promoter holding has declined over recent quarters while public shareholding has increased, but no institutional participation is evident.